Lilly

Corgenix, Eli Lilly ink diagnostic development agreement

Friday, May 24, 2013 10:31 AM

Corgenix Medical, a worldwide developer and marketer of diagnostic test kits, has entered into a collaboration agreement with global pharmaceutical company Eli Lilly to develop diagnostic technology in support of a Lilly oncology pipeline program. The pair will collaborate to further advance this proprietary diagnostic technology originally developed by Lilly.

More... »

Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013 09:38 AM

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

More... »

JDRF appoints David E. Wheadon as executive vice president of research and advocacy

Thursday, May 9, 2013 12:04 PM

Juvenile Diabetes Research Foundation (JDRF), a global organization funding type 1 diabetes (T1D) research, has appointed David E. Wheadon, M.D., as its new executive vice president of research and advocacy.

More... »

Survey underscores importance of patient education and engagement in personalized medicine

Monday, March 25, 2013 02:17 PM

Nearly two out of three people in four major European countries have no awareness of personalized medicine—despite the fact that this evolving discipline has vast implications for Europe's healthcare issues and Europeans' personal health.

More... »

Lilly reassumes sole worldwide rights for novel basal insulin analog

Monday, January 7, 2013 10:55 AM

Global pharmaceutical company Eli Lilly and Boehringer Ingelheim, a Germany-based pharmaceutical company, will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's investigational novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541.

More... »

Heffernan and Koch join Lilly’s autoimmune team

Friday, January 4, 2013 01:17 PM

Global pharmaceutical company Eli Lilly has appointed Michael P. Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis and clinical trials, as a distinguished medical fellow of its autoimmune team. Alisa E. Koch, M.D., a rheumatologist who has won numerous academic awards for her extensive work in rheumatoid arthritis, also joined the team as senior medical fellow.

More... »

Lilly discontinues 1 of 3 phase III rheumatoid arthritis registration studies for tabalumab

Friday, December 14, 2012 11:40 AM

Global pharmaceutical company Eli Lilly is halting one of three phase III rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy.

More... »

Janssen R&D establishes global cross-pharma clinical trial Investigator Databank

Monday, November 19, 2012 10:18 AM

Janssen Research & Development, based in Raritan, N.J., has established a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly are the first two companies to join Janssen in this effort.

More... »

Lilly to expand Indianapolis insulin manufacturing operations

Friday, November 2, 2012 10:38 AM

Global pharmaceutical company Eli Lilly announced a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000-square-foot expansion, which will enable the manufacturing of insulin cartridges to meet the growing diabetes demand in the U.S., represents one of the most significant investments in Lilly's U.S.-based manufacturing operations in the past decade.

More... »

Lilly touts positive results from phase III trials of dulaglutide in T2D

Monday, October 22, 2012 01:24 PM

Global pharmaceutical company Eli Lilly released positive top-line results of three completed phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.

More... »